Rarer Cancers Forum carried out an audit of the policies and processes used by PCTs to determine exceptional funding requests. The findings of the audit were made public in an RCF report entitled Taking Exception (August 2008).

Rarer Cancers Forum carried out an audit of the policies and processes used by PCTs to determine exceptional funding requests. The findings of the audit were made public in an RCF report entitled Taking Exception (August 2008).

Department of Health publishes guidance on exceptional cases processes


Wednesday, January 21, 2009


The Department of Health has published Defining Guiding Principles for Processes supporting Local Decision Making about Medicines.

see article here

Excellent webcast featuring Brian Druker MD and Neil Shah MD talking about CML in general with a brief overview for newly diagnosed patients and then new drug therapy options for patients with resistant disease. Hosted by the Leukaemia and Lymphoma Society U.S.A

more information on DH web site .....here

Winter 2008/2009 Update on Targeted Radiowave Therapy Research

I am pleased to report we continue to make excellent progress in our use of the Kanzius radiofrequency field device to treat human cancers. Since the last update, a manuscript has just been accepted in which we prove we can target gold nanoparticles to malignant cells that express a specific type of receptor at the surface of the cell. This leads to increased levels of the gold nanoparticles in the cancer cells. This enhanced uptake of the nanoparticles led to complete killing of the cancer cells following treatment in the Kanzius radiofrequency field. This paper will be published in late December or early January in the Journal of Experimental Therapeutics. This will be the first manuscript that proves that we can target nanoparticles to a specific abnormality on cancer cells and increase the killing by getting more nanoparticles into the cells.

A team of scientists from the US and China have discovered that grape-seed extract kills laboratory leukemia cells by making them commit suicide, thus showing the potential value of natural compounds in the treatment of cancer.

This is a good resource for understanding the genetics of cancer cells etc.... link to site here

Novartis Oncology, the manufacturer of Gleevec® & Tasigna® has established this Pregnancy Drug Exposure Registry to learn about pregnancy outcomes and the health of women who have taken Gleevec® and/or Tasigna® within six months prior to conception or during pregnancy. The information gathered in this Registry may supplement other sources of data and assist clinicians and patients in weighing the risks or benefits of being exposed to these medications around conception and during pregnancy.